CA-SONY-INTERACTIVE
8.9.2021 16:02:09 CEST | Business Wire | Press release
Sony Interactive Entertainment (“SIE”) announced today that SIE has entered into a definitive agreement to acquire Firesprite Limited, the UK-based videogame studio with a history of developing highly-polished showpieces for cutting-edge hardware. With a partnership spanning more than 8 years and a games portfolio highlighting PlayStation’s technological innovations, Firesprite will play a critical role in strengthening SIE’s exclusive games catalog in genres outside of PlayStation Studios’ core offerings.
Founded by industry veterans from SIE’s Studio Liverpool, Firesprite has a strong record of developing showcase games for PlayStation console and peripheral launches. Over the past few years, Firesprite has partnered with SIE to develop games for the PlayStation®4 and PlayStation®VR launch including The Playroom (PS4) and The Playroom VR (PS VR), both of which showcased unique hardware capabilities with highly-quality gameplay.
Originally a PS VR exclusive, with its most recent release, The Persistence , Firesprite pushed the boundaries of how users interact with the PS VR headset by introducing a groundbreaking virtual reality social element that further demonstrated the studio’s technical and creative capabilities. Later adapted for flat screens in 2018, Firesprite recently released The Persistence Enhanced in June 2021 which optimized the game for PlayStation®5 to include DualSense™ wireless controller haptic feedback, adaptive triggers, and raytraced rendering.
“We are delighted to welcome Firesprite into the PlayStation family,” said Jim Ryan, President & CEO, Sony Interactive Entertainment. “We have a rich history of working with the founders of Firesprite and are excited to grow the PlayStation presence in Liverpool. The portfolio of titles Firesprite has developed has continually demonstrated the team’s ability to transcend traditional gameplay experiences and brilliantly showcase the potential of our hardware.”
“Creating quality, state-of-the-art games has always been at the forefront of Firesprite’s work and I’m confident they will push the bar even further as part of PlayStation Studios,” said Hermen Hulst, Head of PlayStation Studios. “Firesprite’s ability to weave best-in-class gameplay with new technology is exceptional and I think fans will be excited about their creative vision for the future.”
“At Firesprite, we’re always striving to bring something new to a game or genre and developing for new technologies is a driving force of our passion,” said Graeme Ankers, Managing Director, Firesprite. “Joining PlayStation Studios will allow us to amplify this passion, working more closely on cutting-edge hardware without any limitations and furthering our studio’s heritage of creativity and technical innovation to offer some truly unique experiences for PlayStation fans.”
Based in Liverpool, UK Firesprite will join the global development operation of PlayStation Studios and will be the 14th studio to join the PlayStation Studios family. The day-to-day operations post-acquisition will continue to be run by Firesprite’s current management team. Terms of this transaction including the acquisition cost are not disclosed due to contractual commitments.
About Sony Interactive Entertainment
Recognized as a global leader in interactive and digital entertainment, Sony Interactive Entertainment (SIE) is responsible for the PlayStation® brand and family of products and services. PlayStation has delivered innovation to the market since the launch of the original PlayStation in Japan in 1994. The PlayStation family of products and services include PlayStation®5, PlayStation®4, PlayStation®VR, PlayStation™Store, PlayStation®Plus, PlayStation™Now, and acclaimed PlayStation software titles from PlayStation Studios. Headquartered in San Mateo, California, SIE is a wholly owned subsidiary of Sony Group Corporation and has global functions in California, London and Tokyo.
About Firesprite
Founded in 2012 by a group of creative and management veterans with years of industry experience, Firesprite is a visionary game development studio based in the heart of Liverpool’s vibrant game development hub with over 200 team members. Creating a number of showcase games for PlayStation console and peripheral launches over the years, Firesprite’s core focus is developing innovative and memorable experiences for players on cutting edge gaming hardware. At Firesprite, the end player experience always comes first and the team is passionate about how to best combine the disciplines of design, art and code to deliver experiences that surprise and delight.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005275/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom